Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Quantification of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Metastasis of Breast Carcinoma Patients and Assessment of Repeatability (VUBAR) - Pilot Study

NCT03924466 is registered in ClinicalTrials.gov with Universitair Ziekenhuis Brussel as lead sponsor.

NCT NCT03924466
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03924466 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Quantification of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Metastasis of Breast Carcinoma Patients and Assessment of Repeatability (VUBAR) - Pilot Study
Lead sponsor
Universitair Ziekenhuis Brussel
Phase
Phase 2
Overall status
Unknown status
Start date
April 1, 2019
Completion date
December 31, 2024
Enrollment
55 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer, cancer of pancreas, cholangiocarcinoma, colorectal cancer, endometrial cancer, gastric cancer, locally advanced breast cancer, metastatic breast carcinoma, non small cell lung cancer, prostate cancer, salivary gland cancer, solid tumor with intermediate or high her2 expression, urothelial carcinoma, uterine cancer